(Q37855307)

24 August 2017

1 reference

title

Metformin in prostate cancer: two for the price of one. (English)

1 reference

24 August 2017

1 reference

1 reference

6

1 reference

24 August 2017

A Clements

1

1 reference

24 August 2017

B Gao

2

1 reference

24 August 2017

S H O Yeap

3

1 reference

24 August 2017

M K Y Wong

4

1 reference

24 August 2017

S S Ali

5

1 reference

24 August 2017

18 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

22

1 reference

24 August 2017

12

1 reference

24 August 2017

2556-2560

1 reference

24 August 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Cause of death in men diagnosed with prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Changing patterns in competing causes of death in men with prostate cancer: a population based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metabolic complications of androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Insulin sensitivity during combined androgen blockade for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

The metabolic syndrome: A high-risk state for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metabolic syndrome and prostate cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Obesity and prostate cancer: a role for adipokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metabolic syndrome as a prognostic factor for breast cancer recurrences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

AMP-activated protein kinase and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin as an addition to conventional chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin inhibits inflammatory angiogenesis in a murine sponge model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Antidiabetic therapies affect risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Metformin in breast cancer: time for action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Is it time to test metformin in breast cancer clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR037

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDR037

1 reference

24 August 2017

1 reference